The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
 
Gregory J. Riely
Research Funding - Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Rain Therapeutics (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Bayer; Merck
Other Relationship - Mirati Therapeutics; Pfizer; Roche/Genentech; Takeda
 
Egbert F. Smit
Honoraria - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Merck KGaA; Merck KGaA
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Suresh S. Ramalingam
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
Other Relationship - American Cancer Society
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Lilly; Novartis; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Millennium; Polaris; Seagen; Seagen; Takeda
Patents, Royalties, Other Intellectual Property - UptoDate
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Francesco Gelsomino
Honoraria - Lilly
Expert Testimony - AstraZeneca
 
Raymond M. Esper
Employment - Florida Cancer Specialists
 
Ernest Nadal
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Roche; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - American Society for Radiation Oncology; Jazz Pharmaceuticals; Novartis; PharmaMar; Targeted Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Mariano Provencio-Pulla
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck; MSD; Pfizer; Roche; Roche; Takeda
Speakers' Bureau - AstraZeneca; BMS; MSD; Roche; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Boehringer Ingelheim; Bristol Myers Squibb Company; Lilly; MSD; Pierre Fabre; ROCHE; Roche; Takeda
 
Gregory Alan Otterson
Consulting or Advisory Role - Novocure; OncLive/MJH Life Sciences
Research Funding - Apollomics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst)
 
Ibiayi Dagogo-Jack
Honoraria - American Lung Association; American Society of Clinical Oncology; Aptitude Health; Creative Educational Concepts; DAVA Oncology; Foundation Medicine; Medscape; OncLive; Research to Practice; Total Health; Triptych Health Partners
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; BostonGene; Bristol Myers Squibb Foundation; Catalyst Pharmaceuticals; Genentech; Janssen; Novocure; Pfizer; Sanofi; Syros Pharmaceuticals; Xcovery
Research Funding - Array BioPharma (Inst); BostonGene; Calithera Biosciences (Inst); Genentech (Inst); Guardant Health; Novartis (Inst); Pfizer (Inst); Tango Therapeutics; Vivace Therapeutics (Inst)
 
Ann Alcasid
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
Travel, Accommodations, Expenses - Pfizer (I)
 
Tiziana Usari
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer; Viatris
 
Keith D. Wilner
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nuzhat Pathan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Bruce E. Johnson
Consulting or Advisory Role - Abdera Thereapeutics; AstraZeneca; BlueDot; Checkpoint Therapeutics; Daiichi Sankyo; G1 Therapeutics; Genentech; GlaxoSmithKline; Hummingbird Diagnostics; Jazz Pharmaceuticals; Merus NV; Novartis; Simcere
Research Funding - Novartis; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute